(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
-2.75% $ 33.10
@ $25.11
Wydano: 14 vas. 2024 @ 22:41
Zwrot: 31.80%
Poprzedni sygnał: vas. 13 - 22:43
Poprzedni sygnał:
Zwrot: 3.95 %
Live Chart Being Loaded With Signals
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders...
Stats | |
---|---|
Dzisiejszy wolumen | 626 199 |
Średni wolumen | 864 498 |
Kapitalizacja rynkowa | 2.54B |
EPS | $0 ( 2024-04-25 ) |
Następna data zysków | ( $-1.230 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.30 |
ATR14 | $0.0470 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-08 | Southwell David P | Sell | 1 650 | Common Stock |
2024-05-07 | Golden Lee Scott | Sell | 175 | Common Stock |
2024-04-19 | Klein Matthew B. | Sell | 3 361 | Common Stock |
2024-04-17 | Pauwels Eric | Sell | 787 | Common Stock |
2024-04-17 | Klein Matthew B. | Sell | 1 307 | Common Stock |
INSIDER POWER |
---|
73.53 |
Last 98 transactions |
Buy: 1 038 941 | Sell: 203 269 |
Wolumen Korelacja
PTC Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
PTC Therapeutics Inc Korelacja - Waluta/Towar
PTC Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $937.82M |
Zysk brutto: | $649.70M (69.28 %) |
EPS: | $-8.37 |
FY | 2023 |
Przychody: | $937.82M |
Zysk brutto: | $649.70M (69.28 %) |
EPS: | $-8.37 |
FY | 2022 |
Przychody: | $698.80M |
Zysk brutto: | $654.12M (93.61 %) |
EPS: | $-7.79 |
FY | 2021 |
Przychody: | $538.59M |
Zysk brutto: | $506.27M (94.00 %) |
EPS: | $-7.26 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej